Antihyperalgesic Effects of Meteorin in the Rat Chronic Constriction Injury Model: A Replication Study

Jennifer Y. Xie, Chaoling Qiu, Gordon Munro, Kenneth A. Peterson, Frank Porreca

Antihyperalgesic Effects of Meteorin in the Rat Chronic Constriction Injury Model: A Replication Study

2019

Pain (Wolters Kluwer Health)

0
Analgesics administration & dosage therapeutic use
Animals
Disease Models, Animal
Hyperalgesia drug therapy etiology
Index Medicus
Male
Nerve Tissue Proteins administration & dosage therapeutic use
Neuralgia drug therapy etiology
Pain Measurement
Pain Threshold drug effects
Peripheral Nerve Injuries complications
Rats
Rats, Sprague-Dawley
Reproducibility of Results

English

Data from preclinical research have been suggested to suffer from a lack of inherent reproducibility across laboratories. The goal of our study was to replicate findings from a previous report that demonstrated positive effects of Meteorin, a novel neurotrophic factor, in a rat model of neuropathic pain induced by chronic constriction injury (CCI). Notably, 5 to 6 intermittent subcutaneous (s.c.) injections of Meteorin had been reported to produce reversal of mechanical allodynia/thermal hyperalgesia after injury, wherein maximum efficacy of Meteorin was reached slowly and outlasted the elimination of the compound from the blood by several weeks. Here, we evaluated the efficacy of Meteorin in reversing hindpaw mechanical hyperalgesia and cold allodynia in male, Sprague-Dawley rats with CCI. Nociceptive behavior was monitored before and after CCI, and after drug treatment until day 42 after injury. Systemic administration of recombinant mouse Meteorin (0.5 and 1.8 mg/kg, s.c.) at days 10, 12, 14, 17, and 19 after CCI produced a prolonged reversal of neuropathic hypersensitivity with efficacy comparable with that obtained with gabapentin (100 mg/kg, orally). Despite some protocol deviations (eg, nociceptive endpoint, animal vendor, testing laboratory, investigator, etc.) being incurred, these did not affect study outcome. By paying careful attention to key facets of study design, using bioactive material, and confirming drug exposure, the current data have replicated the salient findings of the previous study, promoting confidence in further advancement of this novel molecule as a potential therapy for neuropathic pain.

Pain, vol. 160, no. 8, Aug. 2019, p. 1847

Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the International Association for the Study of Pain. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.

PDF